Automate Your Wheel Strategy on FOLD
With Tiblio's Option Bot, you can configure your own wheel strategy including FOLD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FOLD
- Rev/Share 1.8546
- Book/Share 0.6634
- PB 12.3005
- Debt/Equity 2.1699
- CurrentRatio 3.2092
- ROIC 0.0521
- MktCap 2515233292.0
- FreeCF/Share -0.1588
- PFCF -51.4215
- PE -65.9663
- Debt/Assets 0.5437
- DivYield 0
- ROE -0.1977
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | FOLD | Needham | Hold | Buy | -- | $14 | Sept. 18, 2025 |
| Upgrade | FOLD | Morgan Stanley | Equal Weight | Overweight | -- | $108 | July 17, 2025 |
| Downgrade | FOLD | Morgan Stanley | Overweight | Equal Weight | $17 | $12 | Dec. 13, 2024 |
| Initiation | FOLD | Jefferies | -- | Buy | -- | $18 | Sept. 6, 2024 |
News
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.11 per share a year ago.
Read More
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J.
Read More
Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm
Published: February 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amicus Therapeutics, Inc. (NASDAQ: FOLD) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Read More
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024.
Read More
About Amicus Therapeutics, Inc. (FOLD)
- IPO Date 2007-05-31
- Website https://amicusrx.com
- Industry Biotechnology
- CEO Bradley L. Campbell
- Employees 499